Zum Hauptinhalt springen
xMedica

NCT06605404ClinicalTrials.gov

Pan-tumor MRD Study

Molecular Residual Disease in Solid Tumors: A Prospective Study to Collect Clinical Data and Biospecimens to Support Discovery and Development of Cancer Biomarkers

RekrutiertNimmt laut Registereintrag derzeit Teilnehmende auf.
Diese Studie kontaktieren

Kurz gefasst

The purpose of this observational study is to collect clinical information, blood, and tumor tissue samples from participants diagnosed with stage I, stage II, or operable stage III cancer in select solid tumors. The information collected will be used to…

Beobachtend1.350 Teilnehmende gesucht47 Studienzentren1 Land

Kategorien

In 1 Register registriert

Eine Studie kann in mehreren Registern registriert sein. Wir zeigen sie einmal und verlinken jeden Eintrag, den wir haben.

Die Studieninformationen werden so angezeigt, wie sie vom Register veröffentlicht wurden, in ihrer Originalsprache.

Interesse an dieser Studie?

Anmelden oder ein Konto erstellen um Ihr Interesse zu bekunden und diese Studie zu verfolgen.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2024-09-20; recorded start 2025-01-08
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Not stated: Whether participants are randomly assigned is not stated in the registry recordNo allocation method is recorded
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Not stated: Whether the study is blinded is not stated in the registry recordNo masking information is recorded
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Not stated: No other studies from this sponsor are in this databaseCounted from the lead sponsor named in the record (Paradigm Health)
  • Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
  • The record lists 7 conditions.
  • Lead sponsor type recorded as: industry.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourEXPLORATORY

An exploratory-stage design for a study of this type, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation0/20

    Allocation not stated in the record

  • Blinding0/20

    Masking not stated in the record

  • Control arm0/15

    No comparator arm stated in the record

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre5/8

    Multi-centre: 2 sites

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleLARGE

A large study: 1,350 participants (target), run at 47 sites.

How this score is built
  • Enrolment31/40

    1,350 participants (target)

  • Site count4/25

    2 sites

  • Country count0/15

    Single country

  • Planned duration10/10

    Planned over about 88 months

  • Sponsor scale0/10

    Paradigm Health has led 1 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Zusammenfassung

The purpose of this observational study is to collect clinical information, blood, and tumor tissue samples from participants diagnosed with stage I, stage II, or operable stage III cancer in select solid tumors. The information collected will be used to develop tests to better understand cancer, for example, to improve cancer detection and to assess the risk of cancer coming back. Participants will receive routine standard of care from their doctor and their involvement is expected to last for approximately five and a half (5.5) years.

Erkrankungen

  • Muscle Invasive Bladder Urothelial Carcinoma
  • Esophageal Cancer
  • Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
  • Melanoma (Skin Cancer)
  • NSCLC (Non-small Cell Lung Cancer)
  • Pancreatic (Exocrine Only)
  • Mix of Solid Tumors (MOST)

Eignung

Eignung
GeschlechtAlle
Alter18 Years – Kein Höchstalter
Gesunde FreiwilligeNein
StichprobenverfahrenNON_PROBABILITY_SAMPLE

Studienpopulation

Study participants diagnosed with stage I, stage II, or operable stage III cancer in select solid tumors

Eignung im Wortlaut des Registers

Eligibility Criteria: 1. Age 18 years or older. 2. Confirmed histological or cytological diagnosis of a malignant solid tumor that is either specified in one of the pre-defined tumor cohorts or meets the enrollment criteria for the Mix of Solid Tumors (MOST) cohort (Table 1). 3. Eligible for curative intent therapy, with surgical resection of cancer planned. a. If surgical resection has occurred, enrollment should occur within 3 months of surgical resection and before initiation of adjuvant therapy. 4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2. 5. No systemic therapy for current cancer diagnosis administered before enrollment. 6. Willing and able to comply with required study procedures, including blood sample collection and primary tumor tissue submission from diagnostic biopsy or surgical excision. 7. Has completed all therapy (including endocrine therapy) 3 or more years ago for any previous invasive solid organ malignancy (with exception of nonmelanoma skin cancers) or hematologic malignancy. Individuals with a prior history of noninvasive (in situ) carcinomas may participate if they have received definitive treatment (no washout period required). 8. No concurrent diagnosis of another invasive cancer, except for nonmelanoma skin cancers. 9. No prior allogeneic hematopoietic stem cell transplant. 10. Able and willing to provide informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization for the release of personal health information. Cohort Specific Criteria 11. Muscle-invasive urothelial carcinoma of the bladder and Melanoma Cohorts: Stage II or operable III cancer: 12. Esophageal, Gastric/GEJ, and NSCLC Cohorts: Stage I, II, or operable III cancer. 13. Pancreatic Cohort: Stage I, II or operable III cancer, exocrine only disease. 14. MOST cohort: Stage II or operable stage III solid tumor diagnosis that meets eligibility criteria and is not included in the other cohorts. The following tumor types are excluded: 1. Central nervous system (CNS) malignancies 2. Colorectal cancer 3. Breast cancer 4. Squamous cell skin cancer 5. Basal cell carcinoma 6. Gastrointestinal stromal tumors (GIST) 7. Thyroid cancer 8. Uveal melanoma 9. Low or intermediate grade neuroendocrine tumors ■ Eligible tumor types: High-grade neuroendocrine tumors, including neuroendocrine carcinomas, Merkel cell carcinomas, and small cell lung cancer are permissible 10. Hematologic cancers including multiple myeloma or other plasma cell dyscrasias, Hodgkin\'s lymphoma, non-Hodgkin\'s lymphoma, acute or chronic leukemias including chronic lymphocytic leukemia / small lymphocytic leukemia

Eignung in einfachen Aussagen

Die Kriterien dieses Eintrags wurden noch nicht in einzelne Aussagen aufgeschlüsselt. Der Registertext oben ist vollständig und ist die maßgebliche Fassung.

Studiendesign

Studiendesign
StudientypBeobachtend
PhaseIm Registereintrag nicht angegeben
ZuteilungIm Registereintrag nicht angegeben
InterventionsmodellIm Registereintrag nicht angegeben
Primäres ZielIm Registereintrag nicht angegeben
VerblindungIm Registereintrag nicht angegeben
Teilnahme1.350 Teilnehmende gesucht

Sponsor und Mitwirkende

  • Paradigm Health Sponsor

Studienarme und Interventionen

  • Muscle Invasive Urothelial Carcinoma of the Bladder (MIBC)

    Muscle Invasive Urothelial Carcinoma of the Bladder (MIBC)

  • Esophageal

    Esophageal cancer

  • Gastric and Gastroesophageal Junction (GEJ)

    Gastric and Gastroesophageal Junction (GEJ)

  • Melanoma

    Melanoma

  • Non-small cell lung (NSCLC)

    Non-small cell lung (NSCLC)

  • Pancreatic (exocrine only)

    Pancreatic (exocrine only)

  • Mix of Solid Tumors (MOST)

    Mix of Solid Tumors (MOST)

Interventionen

  • Diagnostischer Test blood and tissue samples

    routine standard of care

  • Sonstige blood and tissue samples

    Routine standard of care

Endpunkte

  1. Primärer Endpunkt

    Blood and tissue biospecimen registry

    To establish a blood and tissue biospecimen resource in participants with operable solid tumors, with clinical, lab, radiographic, and pathology annotation for the discovery, development, and validation of MRD assays.

    Zeitrahmen Observation from enrollment to 5.5 years after enrollment

Daten

Daten
Startdatum8. Januar 2025 (tatsächlich)
Primärer Abschluss1. Dezember 2031 (geschätzt)
Abschluss1. April 2032 (geschätzt)
Erstveröffentlichung20. September 2024 (tatsächlich)
Zuletzt aktualisiert24. September 2026
Ergebnisse veröffentlichtIm Registereintrag nicht angegeben
Status zuletzt bestätigtSeptember 2026

Tatsächlich bedeutet, dass das Ereignis eingetreten ist. Geschätzt bedeutet, dass der Sponsor es erwartet. Die beiden bedeuten Unterschiedliches.

Standorte

47 Studienzentren rekrutieren

United States

United States
EinrichtungStadtBundesland oder RegionStatus
Piedmont Cancer InstituteAtlantaGeorgiaRekrutiert
Guthrie Lourdes Memorial Hospital (GLMH)BinghamtonNew YorkRekrutiert
Alabama OncologyBirminghamAlabamaRekrutiert
Mohtaseb Cancer Center and Blood DisordersBullhead CityArizonaRekrutiert
Gabrail Cancer CenterCantonOhioRekrutiert
Cancer & Blood Specialists of ArizonaCasa GrandeArizonaRekrutiert
Carolina Oncology SpecialistsCharlotteNorth CarolinaRekrutiert
Oncology & Hematology Associates of West BrowardCoral SpringsFloridaRekrutiert
Baptist Health CorbinCorbinKentuckyRekrutiert
Pontchartrain Cancer CenterCovingtonLouisianaRekrutiert
Baptist Health HardinElizabethtownKentuckyRekrutiert
The Melanoma and Skin Cancer InstituteEnglewoodColoradoRekrutiert
San Juan Oncology AssociatesFarmingtonNew MexicoRekrutiert
Los Angeles Cancer Network (LACN)GlendaleCaliforniaRekrutiert
Southeastern Medical Oncology Center (SMOC)GoldsboroNorth CarolinaRekrutiert
The Cancer & Hematology Centers (CHC)Grand RapidsMichiganRekrutiert
Onocology Consultants P.A. (Oncology Consultants [OC Houston])HoustonTexasRekrutiert
Community Clinical TrialsKingwoodTexasRekrutiert
Lancaster General Hospital (UPenn)LancasterPennsylvaniaRekrutiert
Baptist Health LexingtonLexingtonKentuckyRekrutiert
Cancer Partners of NebraskaLincolnNebraskaRekrutiert
CARTILittle RockArkansasRekrutiert
Baptist Health LouisvilleLouisvilleKentuckyRekrutiert
Taylor Cancer Research CenterMaumeeOhioRekrutiert
Cancer Care Specialists of Illinois (CCSI)O'FallonIllinoisRekrutiert
Mid Florida Cancer CentersOrange CityFloridaRekrutiert
Ventura County Hematology Oncology SpecialistsOxnardCaliforniaRekrutiert
Oregon Health & Science University (OHSU)PortlandOregonRekrutiert
Virginia Cancer InstituteRichmondVirginiaRekrutiert
Mayo ClinicRochesterMinnesotaRekrutiert
Medical Oncology Associates of San Diego (MOASD)San DiegoCaliforniaRekrutiert
Medical Oncology Associates of San DiegoSan DiegoCaliforniaRekrutiert
Guthrie FoundationSayrePennsylvaniaRekrutiert
New York Cancer & Blood SpecialistsShirleyNew YorkRekrutiert
Christus Health HighlandsShreveportLouisianaRekrutiert
Highlands Oncology Group (HOG)SpringdaleArkansasRekrutiert
Cox HealthSpringfieldMissouriRekrutiert
Comprehensive Hematology Oncology (CHO)St. PetersburgFloridaRekrutiert
Stockton Hematology Oncology Med GroupStocktonCaliforniaRekrutiert
Northwest Medical Specialties (NWMS)TacomaWashingtonRekrutiert
Christus St. Michael'sTexarkanaTexasRekrutiert
Cotton O'Neil Cancer Center [Stormont Vail]TopekaKansasRekrutiert
Oklahoma Cancer Specialists and Research Institute (OCSRI)TulsaOklahomaRekrutiert
Carle HealthUrbanaIllinoisRekrutiert
Cancer Center of KansasWichitaKansasRekrutiert
Regional Medical Oncology CenterWilsonNorth CarolinaRekrutiert
Cancer Care Associates of York (CCAY)YorkPennsylvaniaRekrutiert

Studiendokumente

In diesem Registereintrag sind keine Dokumente verlinkt.

Änderungen im Zeitverlauf

  1. 24. September 2026

    Studienzentrum hinzugefügt

    45 sites added (47 total)

    247